Genetic Testing of Cerebrospinal Fluid to Diagnose and Monitor Glioblastoma

Inclusion Criteria

• •Cohort A
• •Participants must be able to understand and be willing to sign a written informed consent document
• •Age ≥ 18 years
• •MRI with contrast-enhancing lesion concerning for high-grade glioma in absence of known systemic malignancy
• •Clinical consensus of presumed diagnosis of high grade glioma between (1) neuroradiology (2) neurosurgery; and (3) principal investigator
• •No prior tumor directed therapy
• •Planned radiation therapy for glioblastoma
• •Patients must be willing and able to tolerate MRI scans and/or CT scans w/ contrast
• •Patients must be willing to consent to MSK IRB#12-245
• •Cohort B
• •Participants must be able to understand and be willing to sign a written informed consent document
• •Age ≥ 18 years
• •Histologic confirmed glioblastoma (WHO grade IV), IDH wild type per IHC
• •No prior tumor-directed therapies except surgical resection or biopsy
• •Patients who have gliadel wafers placed during upfront surgery are excluded
• •Planned radiation therapy for glioblastoma
• •Patients must be willing and able to tolerate MRI scans and/or CT scans w/ contrast
• •Patients must be willing to consent to MSK IRB#12-245